News

Early mitral-valve repair dampens tricuspid-valve regurgitation


 

EXPERT ANALYSIS FROM EUROECHO-IMAGING 2014

References

Dr. Mankad also cited a recent editorial written by several of his Mayo Clinic colleagues that synthesized results from the 2011 report as well as from a second Mayo report published in 2014, and a third report from a different group also published in 2014. The authors of the editorial concluded that results from all three studies showed “the performance of early correction of mitral regurgitation is important not only for its own well known benefits (preservation of survival and minimization of late heart failure risk) but also to diminish the late occurrence of functional tricuspid regurgitation (J. Thoracic Cardiovasc. Surgery 2014;148:2810-2).

Because mitral-valve repair often improves tricuspid-valve function and durability, the editorialists suggested “strongly considering” tricuspid repair for a carefully defined, select subgroup of patients. Their list included patients with tricuspid regurgitation that is worse than moderate, right-heart dysfunction, symptoms of right-heart failure, pulmonary hypertension, reduced left ventricular systolic function, cardiomyopathy, or organic tricuspid pathology.

Existing evidence supports leaving the valve alone when patients have a tricuspid regurgitation that is less than moderate when they have also undergone effective correction of degenerative mitral regurgitation. Patients like these are “unlikely ever to have difficulty with the tricuspid valve or the right ventricle,” wrote the authors of the editorial.

Dr. Mankad offered his own suggestions for identifying patients with a tricuspid valve that requires repair at the time of mitral-valve surgery.

“The evidence supports tricuspid-valve repair at the time of mitral-valve surgery if there is tricuspid annular dilatation of more than 4.0 cm measured by three-dimensional echo or greater than moderate tricuspid regurgitation. This is based on observational data and not on results from randomized control trials, but it is what I recommend,” Dr. Mankad said. “I suggest measuring the tricuspid annulus; it is quite easy to do. Directly measuring the annulus size with three-dimensional echo is pretty basic, and I think it is ready for prime time.”

Dr. Mankad had no disclosures.

mzoler@frontlinemedcom.com

On Twitter @mitchelzoler

Pages

Recommended Reading

Africa, Europe, top nuclear cardiology best practice lists
MDedge Cardiology
First appropriate use criteria for transthoracic echocardiography released for suspected pediatric heart disease
MDedge Cardiology
FDA finalizes medical device cybersecurity guidance
MDedge Cardiology
Myocardial geometry, function altered in obese children
MDedge Cardiology
Nonobstructive CAD increases risk of MI and death
MDedge Cardiology
Annual echo an option for cardiac allograft vasculopathy screening
MDedge Cardiology
FDA clears noninvasive method of obtaining FFR measurements
MDedge Cardiology
VIDEO: CT and 3D-echo imaging boost TAVR performance
MDedge Cardiology
VIDEO: Focused cardiac ultrasound aids acute heart failure patients
MDedge Cardiology
Insulin glargine shows cardiac safety in ORIGIN-ECHO
MDedge Cardiology